In this expert analysis of the AGAVE-201 trial data, the efficacy of a monoclonal antibody in treating graft versus host disease is discussed, with the lowest dose of 0.3 mg/kg administered every 2 weeks demonstrating the highest response rates, exceeding 75%.
FDA Enforces Partial Hold on Trial of Seclidemstat in MDS/CMML
July 16th 2024Following the report of a serious and unexpected grade 4 adverse effect, a partial clinical hold has been placed on the phase 1 trial evaluating seclidemstat with azacitidine in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Read More